Edition:
United States

Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

24.05USD
21 Jul 2017
Change (% chg)

$0.47 (+1.99%)
Prev Close
$23.58
Open
$23.42
Day's High
$24.28
Day's Low
$23.38
Volume
1,373,195
Avg. Vol
764,584
52-wk High
$27.86
52-wk Low
$11.30

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals says public offering of 6.25 mln common shares priced at $24 per share
Wednesday, 12 Jul 2017 08:11pm EDT 

July 12 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 6.25 million common shares priced at $24.00per share.Gross proceeds from offering are expected to be $150.0 million.  Full Article

Arena Pharmaceuticals says has cash and cash equivalents as of June 30 of $130.8 mln
Tuesday, 11 Jul 2017 05:28pm EDT 

July 11 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals - Cash and cash equivalents as of June 30, 2017 of $130.8 million, which includes about $0.2 million of cash held by beacon discovery.  Full Article

Arena Pharmaceuticals announces proposed public offering of common stock
Tuesday, 11 Jul 2017 04:05pm EDT 

July 11 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces proposed public offering of common stock.Arena Pharmaceuticals Inc - ‍intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering​.  Full Article

Arena Pharmaceuticals reports topline phase 2 results for Ralinepag
Monday, 10 Jul 2017 04:01pm EDT 

July 10 (Reuters) - Arena Pharmaceuticals Inc ::Arena pharmaceuticals reports positive topline phase 2 results for Ralinepag in patients with pulmonary arterial hypertension.Safety data of phase 2 trial for ralinepag consistent with other drugs acting through prostacyclin receptor-mediated effects.Says Ralinepag also demonstrated numerical improvement in 6-minute walk distance.Primary efficacy analysis successful in phase 2 trial for Ralinepag; significant improvement in pulmonary vascular resistance.  Full Article

Arena Pharmaceuticals says shareholders and board approve reverse stock split
Wednesday, 14 Jun 2017 04:01pm EDT 

June 14 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals announces shareholders and board of directors approve reverse stock split.Arena Pharmaceuticals Inc - stockholders voted to approve proposal authorizing reverse stock split of common shares at an exchange ratio of 1-for-10.  Full Article

Arena Pharmaceuticals reports Q1 loss per share $0.09
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals provides corporate update and reports first quarter 2017 financial results.Q1 loss per share $0.09.Q1 revenue $6.6 million versus I/B/E/S view $8.1 million.Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc says Ralinepag phase 2 study results expected in July.  Full Article

Arena Pharmaceuticals prices 60 mln shares of common stock at price of $1.15/share
Monday, 17 Apr 2017 10:15pm EDT 

April 17 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces pricing of public offering of common stock.Priced an underwritten public offering of 60 million shares of its common stock, at a price of $1.15 per share.  Full Article

Arena Pharmaceuticals announces proposed public offering of common stock
Monday, 17 Apr 2017 04:01pm EDT 

April 17 (Reuters) - Arena Pharmaceuticals Inc -:Arena Pharmaceuticals announces proposed public offering of common stock.  Full Article

Arena Pharma qtrly net income $38.3 mln or $0.16 per share
Tuesday, 14 Mar 2017 04:01pm EDT 

Arena Pharmaceuticals Inc : Arena pharmaceuticals provides corporate update and reports fourth quarter and full-year 2016 financial results . Arena pharmaceuticals inc - qtrly revenues totaled $85.4 million . Arena pharmaceuticals inc - qtrly net income was $38.3 million or $0.16 per share .Arena pharma- expects fy17 net cash used in operating,investing activities to be $80 to $100 million, assuming no additional partnerships.  Full Article

Arena Pharmaceuticals completes enrollment in phase 2 clinical trial for PAH
Wednesday, 7 Dec 2016 08:30am EST 

Arena Pharmaceuticals Inc : Arena Pharmaceuticals - look forward to seeing results from Phase 2 trial mid-year . Arena Pharmaceuticals Inc - study enrolled approximately 60 patients at sites globally .Arena Pharmaceuticals completes enrollment in ralinepag phase 2 clinical trial for pulmonary arterial hypertension (PAH).  Full Article